ARCHIVES

NCI To Test 5,000 DC-Area Jews To Determine Risk Of BRCA 1 Mutation

This article is from The Cancer Letter archive.

Vol. 21 No. 38 | October 6, 1995

Download PDF Visit The Full Archive

Related Articles

FDA Approves Generic Capecitabine

September 20, 2013

Bertagnolli: Why Brigham Stopped Making Morcellation Available Outside Of A Registry Trial

July 4, 2014

Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue

March 29, 2013

Agencies Plan Better Reporting Of Adverse Events In Trials.

February 4, 2000

Panel Recommends 5-FU/Levamisole For Adjuvant Stage 3 Colon Cancer

April 27, 1990

In Brief: Kennedy Seeing Comments On HAS Regulations; Shimkins History of Cancer Now Available

November 11, 1977